Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Chosa

    MCap

    SEK57m

    Last close

    SEK0.80

    ▲ 0.20 (33.33%)

    Vection Technologies

    MCap

    AUD47m

    Last close

    AUD0.04

    ▲ 0.00 (12.90%)

    Metro Bank

    MCap

    GBP684m

    Last close

    GBP1.02

    ▲ 7.90 (8.43%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Executive Interview – MISSION Therapeutics

Executive Interview – MISSION Therapeutics

MISSION Therapeutics, a Touchstone Innovations (AIM: IVO) investee company, is a Cambridge-based drug discovery company that is uniquely placed at the forefront of deubiquitylating enzyme (DUB) drug discovery and development. Since inception in 2011, MISSION has built and developed a proprietary chemistry platform and significant know-how in the generation of potent and selective small molecule DUB inhibitors. Ubiquitin is a small protein found in the vast majority of tissues and is involved in numerous cellular processes, including DNA damage and cell proliferation; DUBs are proteases that cleave ubiquitin from protein/other molecules. Hence targeting ubiquitin through the inhibition of DUBs holds the potential to generate novel drugs to treat cancer and other unmet medical needs, including neurodegenerative disease, inflammation, fibrosis, muscle wasting and infectious disease.

< Previous
Next >

You may also be interested in these:

Healthcare

Recce Pharmaceuticals – executive interview

TMT

VEON – executive interview with CFO Joop Brakenhoff

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free